Search Results

You are looking at 221 - 230 of 529 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Minimally Invasive Techniques for Treating Gynecologic Malignancies

Amanda N. Fader

extent of adjuvant therapy, and managing locoregional recurrence. In fact, laparoscopy has become the gold standard treatment of many gynecologic conditions, “both benign and malignant,” reported Dr. Fader. Many studies have shown improved outcomes with

Full access

Updates in the Treatment of Bone Cancer

J. Sybil Biermann

extremity: a review of 349 cases from a single institution . Cancer Treat Rev 2010 ; 36 : 1 – 7 . 2. Becker WT Dohle J Bernd L . Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy . J

Full access

Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

Thus, in these high-risk patients, offering SLNB would seem reasonable to help define prognostically homogeneous groups for participation in clinical trials of adjuvant therapy. The significance of tumor regression is debatable, with more recent

Full access

Long-Term Therapy of Venous Thromboembolism in Cancer Patients

Michael B. Streiff

adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group . J Clin Oncol 1996 ; 14 : 2731 – 2737 . 13. Holm T Singnomklao T Rutqvist LE Cedermark B . Adjuvant

Full access

Multimodality Approaches to Localized Gastric Cancer

Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani

are perhaps most intriguing, 61 which randomized 1059 patients with stage II or III gastric cancer who underwent D2 surgical resection to either observation or 1 year of oral S-1 adjuvant therapy. S-1 is an orally active combination of tegafur (i

Full access

Point: Sentinel Lymph Node Biopsy Is Indicated for Patients With DCIS

Hiram S. Cody III and Kimberly J. Van Zee

. AJCC Cancer Staging Manual ( Sixth Edition ). New York : Springer-Verlag , 2002 . 58 Ravdin PM Siminoff IA Harvey JA . Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy . J Clin Oncol

Full access

Counterpoint: Sentinel Lymph Node Biopsy Is Not Indicated for Ductal Carcinoma In Situ

Stephen B. Edge and David G. Sheldon

cancer patients receiving no adjuvant therapy . J Clin Oncol 2001 ; 19 : 1468 – 1475 . 37 Gray RJ Cox CE Reintgen DS . Importance of missed axillary micrometastases in breast cancer patients . Breast J 2001 ; 7 : 303 – 307 . 38

Full access

Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials

David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman

Pritchard KI Paterson AHG Fine S . Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor

Full access

Opioid and Benzodiazepine Use in Women With Breast Cancer: More Work on the Horizon

Juan P. Cata and Daniel D. Kim

studies suggest that women aged ≥66 years present a high risk of developing prolonged use of opioids and benzodiazepines. Interestingly, Sakamoto et al 6 found that surgery combined with adjuvant therapies was an independent risk factor for new opioid and

Full access

Role of Surgery for Locally Advanced and Metastatic Renal Cell Carcinoma

Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson

method of operation. However, this information is important to review postoperatively because it may better identify patients with aggressive pathologic features potentially suitable for adjuvant therapy clinical trials. The Role of Lymphadenectomy